41st week of 2019 patent applcation highlights part 23 |
Patent application number | Title | Published |
20190309265 | RECOMBINANT B11 BACTERIOPHAGES AND USES THEREOF - The present disclosure provides compositions including recombinant B 11 bacteriophages, methods for making the same, and uses thereof. The recombinant B 11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample. | 2019-10-10 |
20190309266 | NOVEL NADH-DEPENDENT ENZYME MUTANTS TO CONVERT ACETONE INTO ISOPROPANOL - The present disclosure relates to biological processes and systems for the production of isopropanol and/or acetone utilizing modified alcohol dehydrogenases that exhibit increased activity with NADH as a cofactor. The disclosure further relates to polynucleotides and polypeptides of the modified alcohol dehydrogenases, and host cells containing the polynucleotides and expressing the polypeptides. | 2019-10-10 |
20190309267 | KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE - The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine. | 2019-10-10 |
20190309268 | GLYCEROL FREE ETHANOL PRODUCTION - The invention relates to a recombinant cell, preferably a yeast cell comprising: a) one or more heterologous genes encoding a glycerol dehydrogenase activity; b) one or more genes encoding a dihydroxyacetone kinase (E.C. 2.7.1.28 and/or E.C. 2.7.1.29); c) one or more heterologous genes encoding a ribulose-1,5-biphosphate carboxylase oxygenase (EC 4.1.1.39, RuBisCO); and d) one or more heterologous genes encoding a phosphoribulokinase (EC 2.7.1.19, PRK); and optionally e) one or more heterologous genes encoding for a glycerol transporter. This cell can be used for the production of ethanol and advantageously produces little or no glycerol. | 2019-10-10 |
20190309269 | THERAPEUTIC CELL SYSTEMS AND METHODS FOR TREATING HYPERURICEMIA AND GOUT - The present disclosure relates to erythroid cells that have been engineered to comprise a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered erythroid cells of the present disclosure are useful in degrading uric acid inside the engineered erythroid cell. The engineered erythroid cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered erythroid cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout. | 2019-10-10 |
20190309270 | DIRECTED EVOLUTION OF CYP52A12 GENE AND ITS USE IN DICARBOXYLIC ACID PRODUCTION - The invention relates to the directed evolution of CYP52A12 gene and the use thereof for the production of a dicarboxylic acid. In particular, it relates to a method of preparing a long chain dicarboxylic acid producing strain by using directed evolution and homologous recombination, a strain obtained by the method that is capable of producing a long chain dicarboxylic acid under an acidic condition and the use thereof. In particular, the invention relates to a method of preparing a long chain dicarboxylic acid producing strain by directed evolution of CYP52A12 gene and homologous recombination, a strain obtained by the method that is capable of producing a long chain dicarboxylic acid under an acidic condition and the use thereof. By directed evolution of CYP52A12 gene, one strain which has a base mutation at the promoter region of said gene and is capable of producing a long chain dicarboxylic acid under an acidic condition in a shortened fermentation time is screened out in the invention. | 2019-10-10 |
20190309271 | THERAPEUTIC CELL SYSTEMS AND METHODS FOR TREATING HOMOCYSTINURIA - The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria. | 2019-10-10 |
20190309272 | Genetically Modified Cell Lines Including a TP53 Modification and Methods of Use - The present disclosure is directed to genetically engineered cell lines which include a modification to knockout a portion of the TP53 gene. Embodiments disclosed herein provide aspects of the knockout cell lines, methods for producing the knockout cell lines, in vitro assays using the knockout cell lines, and kits including the knockout cell lines. In certain implementations, the embodiments can provide doctors and patients improved tools for determining a treatment or for comparing treatments for patients having tumors that include a TP53 mutation. | 2019-10-10 |
20190309273 | Variants of Phosphotriesterase for the Hydrolysis and Detoxification of Nerve Agents - Variants of phosphotriesterase have been created that exhibit enhanced hydrolysis of V-type and G-type nerve agents over wild-type phosphotriesterase. V- and G-type nerve agents have an S | 2019-10-10 |
20190309274 | IL-10 RECEPTOR ALPHA HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE - The invention provides improved genome editing compositions and methods for editing an IL-10Rα gene. The invention further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, GVHD, a transplant rejection, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency. | 2019-10-10 |
20190309275 | MODIFIED NUCLEIC ACID EDITING SYSTEMS FOR TETHERING DONOR DNA - The technology relates to a composition for tethering donor DNA to a nuclease, the composition comprising a nucleic acid comprising donor DNA and a consensus sequence for a DNA binding domain; and at least one of: a fusion protein comprising a nuclease coupled to a DNA binding domain for binding the consensus sequence; and a nucleic acid encoding the fusion protein. | 2019-10-10 |
20190309276 | PROTEIN PRODUCTION IN FILAMENTOUS FUNGAL CELLS IN THE ABSENCE OF INDUCING SUBSTRATES - Certain embodiments of the disclosure are directed to variant filamentous fungal cells, compositions thereof and methods thereof for increased production of one or more proteins of interest. More particularly, in certain embodiments, the disclosure is directed to variant filamentous fungal (host) cells derived from parental filamentous fungal cells, wherein the variant host cells comprise a genetic modification which enables the expression/production of a protein of interest (POI) in the absence of inducing substrate. In certain embodiments, a variant fungal host cell of the disclosure comprises a genetic modification which increases the expression of a variant activator of cellulase expression 3 (ace3) gene encoding an Ace3 protein referred to herein as Ace3-L. | 2019-10-10 |
20190309277 | FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent (eg clostridial neurotoxin L-chain or IgA protease); a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent (eg GALR1, GALR2, or GALR3 receptor); a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent (eg HN domain of clostridial neurotoxin); a first spacer located between the non-cytotoxic protease and the protease cleavage site, wherein said first spacer comprises an amino acid sequence of from 4 to 25 amino acid residues; and a second spacer located between the galanin Targeting Moiety and the translocation domain, wherein said second spacer comprises an amino acid sequence of from 4 to 35 amino acid residues. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described (eg of treating, preventing or ameliorating pain). | 2019-10-10 |
20190309278 | PROTEASE VARIANTS AND USES THEREOF - Disclosed herein is one or more subtilisin variants, nucleic acids encoding same, and compositions and methods related to the production and uses thereof, including one or more subtilisin variants that has improved stability and/or soil removal compared to one or more reference subtilisin. | 2019-10-10 |
20190309279 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2019-10-10 |
20190309280 | PROCOAGULANT COMPOUNDS - The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disefficacy orders using the disclosed compounds, methods of enhancing in vivo of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG. | 2019-10-10 |
20190309281 | Method for Promoting Acetylglucosamine Synthesis of Bacillus Subtilis - The present invention relates to a method for promoting acetylglucosamine synthesis of | 2019-10-10 |
20190309282 | MESOPOROUS CATALYSTS OF MAGNETIC NANOPARTICLES AND FREE-RADICAL-PRODUCING ENZYMES, AND METHODS OF USE - A composition comprising mesoporous aggregates of magnetic nanoparticles and free-radical producing enzyme (i.e., enzyme-bound mesoporous aggregates), wherein the mesoporous aggregates of magnetic nanoparticles have mesopores in which the free-radical-producing enzyme is embedded. Methods for synthesizing the enzyme-bound mesoporous aggregates are also described. Processes that use said enzyme-bound mesoporous aggregates for depolymerizing lignin, removing aromatic contaminants from water, and polymerizing monomers polymerizable by a free-radical reaction are also described. | 2019-10-10 |
20190309283 | METHOD FOR PREPARING LONG-CHAIN SINGLE-STRANDED DNA - To provide a method for preparing a long-chain single-stranded DNA that has an accurate sequence having neither internal mutation nor terminal deletion, is homogeneous and is not contaminated with double-stranded DNAs. A target log-chain single-stranded DNA is prepared by: cloning the target DNA using a vector having nicking endonuclease recognition sites or a nicking endonuclease recognition site and a sequence-specific double-strand cleaving endonuclease recognition site; cleaving the vector by using appropriate enzyme(s); electrophoresing the same; and then cutting out a gel that contains the target single-stranded DNA to thereby prepare the target long-chain single-stranded DNA. | 2019-10-10 |
20190309284 | METHODS AND KITS FOR DYNAMIC TARGETED HYPERMUTATION - Disclosed herein are methodologies and kits for dynamic targeted hypermutation that harness the enzymatic activity of a polynucleic acid-binding protein fused to a nucleobase-editing enzyme to specifically target mutations across a region of interest. These methodologies and kits facilitate the rapid creation of diverse DNA libraries in vivo or in vitro. | 2019-10-10 |
20190309285 | GENES EXPRESSED IN MENTAL ILLNESS AND MOOD DISORDERS - The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia. attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose. to stage, to treat. and/or to monitor the treatment of a subject with mental illness. | 2019-10-10 |
20190309286 | CHIMERIC PROTEINS - This invention relates to modular proteins that interact with one or more target molecules. The chimeric proteins comprise two or more repeat domains, such as tetratricopeptide repeat domains; inter-repeat loops linking the repeat domains; and one or more peptide ligands. Each peptide ligand is located in an inter-repeat loop or at the N or C terminus of the chimeric protein. The peptide ligands may include heterologous peptidyl binding motifs, such as short linear motifs (SLiMs). Chimeric proteins with various configurations and methods for their production and use are provided. | 2019-10-10 |
20190309287 | ASSAYS TO IDENTIFY GENETIC ELEMENTS AFFECTING PHENOTYPE - The present invention comprises generally applicable methods for identifying endogenous physiologically relevant genetic elements that affects a intracellular phenotype of interest. In the methods, non-living cells that have been subjected to a mutagenesis treatment are sorted based on phenotype and analyzed to identify the genetic element. By use of these methods, elements previously unknown to be involved in a phenotype can be identified, for example in relationship to health conditions, external stress or drug response, in particular in cancer. | 2019-10-10 |
20190309288 | TARGETED MUTAGENESIS - Provided herein is technology relating to the mutagenesis of nucleic acids, e.g., for directed evolution, and particularly, but not exclusively, to methods, compositions, and kits for producing nucleic acids and/or proteins comprising mutations and substitutions within specific target sequences. | 2019-10-10 |
20190309289 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING - The present disclosure provides compositions and methods for genomic engineering. | 2019-10-10 |
20190309290 | Improved Methods for Modification of Target Nucleic Acids - Methods for modification of target nucleic acids. The method involves a construct in which guide RNA is covalently linked to donor RNA (fusion NA) to be introduced into the target nucleic acid by homologous recombination and is based on the introduction of a nuclease, e.g. CRISPR or TALEN, into the cell containing the target nucleic acid. The fusion NA may be introduced as a DNA vector. | 2019-10-10 |
20190309291 | CCCTC-Binding Factor (CTCF) RNA Interactome - This invention relates to methods and compositions for selectively reactivating or downregulating certain genes, e.g., genes regulated by zinc-finger protein CCCTC-binding factor (CTCF) on autosomes (e.g., imprinted genes, tumor suppressors, cancer) and the inactive X chromosome (Xi), e.g., genes associated with X-linked diseases, e.g., Rett | 2019-10-10 |
20190309292 | Compounds and Methods for Enhanced Cellular Uptake - Described herein are conjugated modified oligonucleotides that are complementary to a target RNA. The conjugate facilitates cellular uptake of the modified oligonucleotide, resulting improved potency. | 2019-10-10 |
20190309293 | Compositions and Methods for Inhibiting Expression of Transthyretin - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 2019-10-10 |
20190309295 | TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes. | 2019-10-10 |
20190309296 | MATERIALS AND METHODS FOR RAPID AND SENSITIVE DETECTION OF SMALL-MOLECULE TARGETS - The subject invention provides methods, assays and products for detecting small-molecules in a sample, in particular, in both clinical and field settings. The method for detecting a small-molecule target in a sample comprises providing a sample, contacting the sample with an aptamer-based sensor selective for the small-molecule target, and sensitively and rapidly detecting the small-molecule target in the sample. Specifically, the method utilizes EATR-amplified small-molecule sensors based on cooperative binding split aptamers (CBSAs). | 2019-10-10 |
20190309297 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules. | 2019-10-10 |
20190309298 | ANTIVIRAL AGENTS - An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of Zika virus (ZIKV). The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating ZIKV-mediated disease, a method of preventing ZIKV-mediated disease, a method of reducing or preventing the replication of ZIKV in a host cell, a method of controlling the spread of ZIKV in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or ZIKV-mediated disease. | 2019-10-10 |
20190309299 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS - This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer. | 2019-10-10 |
20190309300 | INHIBITORS OF CYTOPLASMIC HISTONE DEACETYLASE 4 COMPLEX FOR TREATING OR PREVENTING VASCULAR OR VALVE CALCIFICATION - A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA. | 2019-10-10 |
20190309301 | COMPOSITIONS AND METHODS FOR IMPROVING IMMUNE SYSTEM FUNCTION - Provided herein are compositions and methods for improving immune system function. In particular, provided herein are compositions, methods, and uses of YY1 and EZH2 inhibitors for preventing and reversing T-cell exhaustion (e.g., for use in immunotherapy). | 2019-10-10 |
20190309302 | ANTISENSE OLIGONUCLEOTIDES - The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided. | 2019-10-10 |
20190309303 | TREATMENT OF TUMOR SUPPRESSOR GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO THE GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes. | 2019-10-10 |
20190309304 | Antisense Compounds Targeting Leucine-Rich Repeat Kinase 2(LRRK2) For The Treatment of Parkinsons Disease - The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease. | 2019-10-10 |
20190309305 | ALLELE-SPECIFIC SILENCING THERAPY FOR DYNAMIN 2-RELATED DISEASES - The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2. | 2019-10-10 |
20190309306 | RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof - The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described. | 2019-10-10 |
20190309307 | REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF - The present disclosure relates to reagents for producing T-cells comprising non-functional T-cell receptors (TCR), including T-cells which also express chimeric antigen receptors (CAR), i.e., CAR-T cells, compositions comprising said reagents and T-cells, and uses of said CAR-T cells in therapy e.g., adoptive therapy. | 2019-10-10 |
20190309308 | Method of Treating Cancer and Method of Sensitizing Cancer Cells to the Action of Chemotherapeutic Agents via Growth Hormone Receptor Antagonists or Knock Down - Various aspects of the present invention relate to a method of treating cancer in a subject having cancer cells, wherein the cancer cells possess at least one growth hormone receptor, and wherein the method includes controlling an action of the growth hormone receptor. In various non-limiting embodiments, controlling an action of the growth hormone receptor may occur via knock down of the growth hormone receptor, or may be caused by inhibiting growth hormone action, such as via the use of antibodies directed against growth hormone or the growth hormone receptor. Methods may also relate to administering an antagonist of the growth hormone receptor, and administering at least one anti-tumor drug in concert with administration of the antagonist. Another aspect may include a method of maintaining an anti-tumor drug in cancer cells of a subject by controlling an action of at least one growth hormone receptor in the cancer cells. | 2019-10-10 |
20190309309 | BACTERIAL CELLS WITH IMPROVED TOLERANCE TO POLYOLS - The present invention relates to bacterial cells genetically modified to improve their tolerance to certain commodity chemicals, such as diols and other polyols, and to methods of preparing and using such bacterial cells for production of polyols and other compounds. | 2019-10-10 |
20190309310 | Gold Optimized CAR T-cells - Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell. | 2019-10-10 |
20190309311 | Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy Regeneration - The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes. | 2019-10-10 |
20190309312 | DISPLAY SYSTEMS FOR PROTEINS OF INTEREST - Described herein is a protein display selection method which uncouples a protein of interest (POI) library from the display selection system. Display of the POI can be achieved by forming a covalent bond between the POI and the anchor protein post expression either by enzymatic protein ligation (e.g. SpyLigase, SnoopLigase, sortase, butelase, peptiligase etc.) or by spontaneous covalent bond formation (e.g. SpyTag/SpyCatcher, SnoopTag/SnoopCatcher, etc.). The POI library is fused to a tethering sequence, for example SpyTag, at the C-terminus of the POI which then forms a covalent bond to a capture sequence found on an anchor protein, for example, the SpyCatcher-fused anchor protein, e.g., a SpyCatcher-geneIII protein (SpyCatcher-pIII) fusion, for the most common form of phage display. Nucleic acid constructs, host cell systems and methods of producing the protein display systems are also provided. | 2019-10-10 |
20190309313 | Dual Cistronic Bacterial Expression System - The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria | 2019-10-10 |
20190309314 | YEAST SYNTHETIC BIOLOGY PLATFORM FOR IDENTIFYING SHIKIMATE PATHWAY ENZYME INHIBITORS - Provided are compositions and methods for compound discovery. Modified yeast that have their endogenous yeast shikimate pathway disrupted or deleted, and replaced with homologous pathway genes from one or more distinct organisms, are provided and used in assays of test agents. The homologous pathway genes are designed to supplement the disrupted or deleted shikimate pathway genes. The assays are designed to identify whether or not the test agents can interfere with the function of enzymes in the shikimate pathway from organisms that are distinct from the yeast avatar hosts. In embodiments, the disruption/deletion of the yeast endogenous shikimate pathway results in the yeast being incapable of producing chorismic acid. | 2019-10-10 |
20190309315 | GENETICALLY ENGINEERED CANDIDA UTILIS CAPABLE OF DEGRADING AND UTILIZING KITCHEN WASTE AND CONSTRUCTION METHOD THEREFOR - Provided is a genetically engineered | 2019-10-10 |
20190309316 | METHOD OF GENERATING STRESS TOLERANT PLANTS OVER-EXPRESSING CARRP1, REAGENTS AND USES THEREOF - A method of generating stress tolerant plants which heterologously express a protein of amino acid sequence as set forth in SEQ ID NO: 2. Also, provided are stress tolerant plants which are able to resist varied biotic and abiotic environmental stressors. | 2019-10-10 |
20190309317 | COMPOSITIONS AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS - The present disclosure provides the identification of tobacco Nic1 locus. Also provided are tobacco plants with altered total alkaloid and nicotine levels and commercially acceptable leaf grade, their development via breeding or transgenic approaches, and production of tobacco products from these tobacco plants. Also provided are compositions and methods for producing tobacco plants having novel Nic1 mutations or alleles to reduce nicotine levels. Further provided are sequence polymorphisms and molecular markers for breeding tobacco with reduced nicotine or nicotine free while maintaining tobacco leaf grade and tobacco product quality. | 2019-10-10 |
20190309318 | PLANT TOLERANCE TO STRESS THROUGH THE CONTROL OF CHLOROPLAST STABILITY - The chloroplast vesiculation (CV) gene encodes a protein associated with stress-induced chloroplast degradation. Inhibiting expression or activity of the protein inhibits or delays stress-induced chloroplast degradation and confers tolerance to a variety of stress conditions. Alternatively, enhancing CV expression or activity promotes chloroplast degradation and enhances nutrient assimilation in desired sink tissues, such as young leaves, fruit, or seeds. | 2019-10-10 |
20190309319 | PHYTOPHTHORA RESISTANT PLANTS BELONGING TO THE SOLANACEAE FAMILY - The present invention relates to a plant belonging to the Solanaceae family wherein said plant comprises a genetic trait providing | 2019-10-10 |
20190309320 | CUCURBITA PLANT RESISTANT TO POTYVIRUS - The present invention relates to a | 2019-10-10 |
20190309321 | PHI-4 POLYPEPTIDES AND METHODS FOR THEIR USE - Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity. | 2019-10-10 |
20190309322 | CHIMERIC POST-TRANSCRIPTIONAL REGULATORY ELEMENT - The present disclosure relates to chimeric post-transcriptional regulatory elements (PRE) and vectors useful for expressing a protein in a cell. The PRE contains alpha, beta and optionally gamma subelements selected from different native PRE sequences and are discovered to be more potent than their native counterparts. | 2019-10-10 |
20190309323 | PROMOTER WITH AN ENRICHED CYTOSINE-GUANINE DINUCLEOTIDE REGION, VECTORS, CELLULAR LINES, METHOD FOR PRODUCING RECOMBINANT PROTEIN - The present invention relates to the field of genetic engineering, preferably the expression of recombinant proteins (RP). In particular, the invention relates to a promoter and variants thereof having an equal function and more than 90% sequence identity. The promoter comprises a fragment of 1147 base pairs (bp) of a first promoter, promoter of the β-actin gene of the | 2019-10-10 |
20190309324 | AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others - The present invention presents a sequence of the AAV/UPR-plus virus, a genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's and Huntington's diseases, among others, as presented in the in vitro studies shown in FIG. | 2019-10-10 |
20190309325 | VIRUS COMPOSITION AND METHOD FOR SEPARATION USING SAME - (Technical problems to be solved) To provide a method for selecting mineral of molybdenum. | 2019-10-10 |
20190309326 | DUAL OVERLAPPING ADENO-ASSOCIATED VIRAL VECTOR SYSTEM FOR EXPRESSING ABCA4 - The present invention provides an adeno-associated viral (AAV) vector system for expressing a human ABCA4 protein in a target cell, the AAV vector system comprising a first AAV vector comprising a first nucleic acid sequence and a second AAV vector comprising a second nucleic acid sequence; wherein the first nucleic acid sequence comprises a 5′ end portion of an ABCA4 coding sequence (CDS) and the second nucleic acid sequence comprises a 3′ end portion of an ABCA4 CDS, and the 5′ end portion and the 3′ end portion together encompass the entire ABCA4 CDS; wherein the first nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 105 to 3597 of SEQ ID NO: 1; wherein the second nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 3806 to 6926 of SEQ ID NO: 1; wherein the first nucleic acid sequence and the second nucleic acid sequence each comprise a region of sequence overlap with the other; and wherein the region of sequence overlap comprises at least about 20 contiguous nucleotides of a nucleic acid sequence corresponding to nucleotides 3598 to 3805 of SEQ ID NO: 1. Also provided are uses of AAV vector systems in the prevention or treatment of disease. | 2019-10-10 |
20190309327 | IS-TARGETING SYSTEM FOR GENE INSERTION AND GENETIC ENGINEERING IN DEINOCOCCUS BACTERIA - The present invention relates to methods and compositions for chromosome integration of nucleic acids into | 2019-10-10 |
20190309328 | RECOMBINANT CELLS AND METHOD FOR PRODUCING ISOPRENE OR TERPENE - To provide a recombinant cell being an anaerobic archaeon, including a gene encoding isoprene synthase, a gene encoding monoterpene synthase, a gene encoding sesquiterpene synthase, a gene encoding diterpene synthase, a gene encoding squalene synthase, or a gene encoding phytoene synthase as a first foreign gene, wherein the first foreign gene is expressed, and the recombinant cell is capable of producing isoprene or terpene having 10, 15, 20, 30, or 40 carbon atoms. | 2019-10-10 |
20190309329 | PRIMARY ALCOHOL PRODUCING ORGANISMS - The invention provides a non-naturally occurring microbial organism having a microbial organism having at least one exogenous gene insertion and/or one or more gene disruptions that confer production of primary alcohols. A method for producing long chain alcohols includes culturing these non-naturally occurring microbial organisms. | 2019-10-10 |
20190309330 | PRODUCTION OF FRAMBINONE BY A RECOMBINANT FUNGAL MICROORGANISM - The invention relates to a genetically modified fungal microorganism for the production of frambinone, said microorganism having the following characteristics: —the capacity to produce frambinone from tyrosine; and —a limited capacity or no capacity to break tyrosine down into tyrosol, p-hydroxyphenylacetaldehyde and/or p-hydroxyphenylacetate; and to the use of same for producing frambinone. | 2019-10-10 |
20190309331 | Host cells and methods for producing diacid compounds - The present invention provides for a genetically modified host cell and related methods and materials for the biocatalytic production of an α,ω-dicarboxylic acids (DCAs) and/or mono-methyl ester derivatives of dicarboxylic acids (DCAMMEs). | 2019-10-10 |
20190309332 | FERMENTATION PROCESS - A fermentation product manufacturing process includes fermenting under fermentation conditions in an aqueous fermentation medium in a fermentation reactor a carbohydrate source with a microorganism capable of converting the carbohydrate into a fermentation product which is a salt or a product with a boiling point above the boiling point of water, during the process withdrawing part of the medium including biomass from the reactor in the form of a recycle stream, providing the stream including biomass to a pressure vessel wherein the pressure is such that the temperature of the stream decreases 1-8° C., as compared to the temperature of the medium in the reactor, by the evaporation of water, and recycling the cooled recycle stream to the reactor. The process makes it possible to obtain a homogeneous temperature profile of the fermentation medium with limited occurrence of hot or cool spots within the reactor which results in improved fermentation performance. | 2019-10-10 |
20190309333 | MICROORGANISM WITH IMPROVED L-THREONINE PRODUCING CAPABILITY, AND METHOD FOR PRODUCING L-THREONINE BY USING THE SAME - The present invention relates to a novel variant RNA polymerase sigma factor 70 (σ | 2019-10-10 |
20190309334 | NOVEL B-1,6-ENDOGLUCANASE PRODUCING GENTIOBIOSE OR GLUCOSE FROM B-GLUCAN - The present invention relates to a novel β-1,6-endoglucanase producing gentiobiose or glucose from β-glucan, and more specifically, the present invention provides an effect of producing gentiobiose or glucose at high yield through β-1,6-endoglucanase showing β-1,6-endoglucanase activity on β-glucan. | 2019-10-10 |
20190309335 | PROCESS FOR PREPARING A DYED BIOPOLYMER AND PRODUCTS THEREOF - The present invention relates to a process for the production of a dyed biopolymer comprising the steps of providing at least one biopolymer-producing microorganism, providing at least one dye-producing microorganism, culturing said at least one biopolymer-producing microorganism to produce at least a biopolymer, and culturing said dye-producing microorganism wherein said dye-producing microorganism produce at least a dye suitable to dye at least part of said biopolymer, whereby a dyed biopolymer is obtained. The present invention also relates to a dyed biopolymer, to process for the production of a dyed composite article comprising at least the dyed biopolymer and to articles comprising the dyed biopolymer. | 2019-10-10 |
20190309336 | IMPROVED PROCESS FOR THE PRODUCTION OF FUCOSYLATED OLIGOSACCHARIDES - The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein. | 2019-10-10 |
20190309337 | RNA POLYMERASE VARIANTS - The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction. | 2019-10-10 |
20190309338 | Multiple Protease Deficient Filamentous Fungal Cells and Methods of Use Thereof - The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells. | 2019-10-10 |
20190309339 | FERMENTATION PROCESS WITH PICHIA YEAST EXPRESSING RECOMBINANT PROTEIN - The present invention discloses a fermentation process with a | 2019-10-10 |
20190309340 | METHOD OF CONTINUOUSLY PRODUCING GLUTATHIONE USING PHOTOSYNTHETIC MEMBRANE VESICLES - The present invention relates to a method of producing glutathione, wherein photosynthetic membrane vesicles and enzymes catalyzing glutathione synthesis are combined and glutamate, cysteine and glycine are used as reaction substrates. As enzymes catalyzing glutathione synthesis, γ-glutamylcysteine synthetase and glutathione synthetase may be used together, or bifunctional glutathione synthetase may be used alone. According to the conventional methods, there is a problem in that expensive adenosine triphosphate should be continuously supplied when glutathione is produced. However, according to the present invention, since photosynthetic membrane vesicles are used as a source to regenerate adenosine triphosphate, it is possible to continuously produce glutathione without additionally adding adenosine triphosphate, thereby reducing production costs of glutathione. | 2019-10-10 |
20190309341 | METHODS AND COMPOSITIONS FOR DETECTING OR MEASURING CASPASES OR APOPTOSIS - Provided herein are compounds, enzyme substrates, compositions, kits, uses, and methods for detecting the presence or absence of a caspase enzyme, measuring the activity of a caspase enzyme, or detecting the presence or absence of apoptosis. The detection or measurement can occur through intracellular cleavage of a compound or enzyme substrate, which can lead to an increase in fluorescence, e.g., in the violet or red channel, through liberation of a nucleic acid binding dye from a peptide, such as liberation of a DNA-binding dye from a negatively charged peptide comprising a sequence recognized and cleaved by a caspase | 2019-10-10 |
20190309342 | THERMAL STABLE LUCIFERASE WITH IMPROVED RESISTANCE TO INHIBITION BY LUCIFERIN BREAK-DOWN PRODUCTS - Provided herein are inhibitor-resistant luciferase mutants, and methods of use thereof. In particular, luciferase mutants are provided that are thermal stable and exhibit improved stability in the presence of luciferin break-down products, such as dehydroluciferin. Further provided are assay systems comprising inhibitor-resistant luciferase mutants and amino acid sequences of the inhibitor-resistant luciferase mutants. | 2019-10-10 |
20190309343 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS - The present invention provides methods, compositions and devices for stabilizing the extracellular nucleic acid population in a cell-containing biological sample using an apoptosis inhibitor, preferably a caspase inhibitor, a hypertonic agent and/or a compound according to formula 1 as defined in the claims. | 2019-10-10 |
20190309344 | CAPSULE FOR LYOPHILIZED REAGENT STORAGE AND DELIVERY - A capsule to store and deliver lyophilized reagents is described. The lyophilized reagent capsule is configured to store a lyophilized reagent for at least five days, and is further configured to deliver a lyophilized reagent to a biological sample. The capsule includes a top, a bottom, and a lyophilized reagent. A method for delivering the lyophilized reagent via the capsule and without the use of pipettes to deliver the lyophilized reagents is described. The capsule may be part of a lyophilized reagent capsule kit. | 2019-10-10 |
20190309345 | CLINICAL APPLICATION OF CELL FREE DNA TECHNOLOGIES TO NON-INVASIVE PRENATAL DIAGNOSIS AND OTHER LIQUID BIOPSIES - Embodiments of the disclosure include methods of prenatal testing using non-invasive means that identify single gene disorders. In specific embodiments the methods are non-invasive and employ tagging circulating cell-free fetal DNA from the biological mother with particular adaptors that employ unique barcodes, followed by steps to enrich targets and steps for thorough sequencing. | 2019-10-10 |
20190309346 | Combined Extraction and PCR Systems - The disclosure provides methods and systems for analyzing fluid samples comprising obtaining fluid samples in at least one cavity of a substrate and introducing also buffers and/or reagents in the cavity, performing nucleic acid extraction and/or purification in the cavity, and performing nucleic acid amplification in the same cavity. | 2019-10-10 |
20190309347 | METHOD AND KIT FOR DETECTING, DISCRIMINATING AND IDENTIFYING BORRELIA SPECIES PRESENT IN A SAMPLE OF HUMAN OR ANIMAL ORIGIN - The present invention concerns a method for detecting, discriminating and identifying | 2019-10-10 |
20190309348 | METHOD FOR CHARACTERIZING AFFINITY AGENTS AND RELATED APPARATUS - A method is provided for characterizing analyte-specific affinity agents having affinity for an analyte. The method includes providing a library of candidate affinity agents, providing a surface suitable for adhesion of the library of candidate affinity agents, and exposing the library of candidate affinity agents to the surface to thereby adhere the library of candidate affinity agents to the surface. It also includes providing an analyte, and causing the analyte to contact the surface to thereby expose the library of candidate affinity agents adhered to the surface to the analyte, to cause selected ones of the candidate affinity agents to react with the analyte to form reaction products, and to create an output fluid that comprises the reaction products. In addition, the method includes analyzing the output fluid to characterize the analyte-specific affinity agents associated with the respective reaction products. The candidate affinity agents may take a number of forms, including nucleic acids, peptides, genomers and others. Related apparatus also are provided. | 2019-10-10 |
20190309349 | METHOD FOR DETECTION OF A PCR PRODUCT - A method for detecting a nucleic acid molecule in a biological sample includes amplifying a nucleic acid molecule to generate an amplicon having a single 5′-tail and coupling the 5′-tail to one of a plurality of capture probes on a surface of a sensor. The amplicon is converted to a single strand molecule and a target-specific catalyst cluster is bound to the single strand molecule. The catalyst cluster is subjected to metallization in order to detect the target nucleic acid. | 2019-10-10 |
20190309350 | MEMBRANE-SPANNING NANOPORES - A membrane-spanning nanopore is provided that comprises: i. at least one scaffold polynucleotide strand; ii. a plurality of staple polynucleotide strands; and iii. at least one hydrophobically-modified polynucleotide strand, wherein the at least one hydropho-bically-modified polynucleotide strand comprises a polynucleotide strand and a hydrophobic moiety; wherein each of the plurality of staple polynucleotide strands hybridises to the at least one scaffold polynucleotide strand to form the three-dimensional structure of the membrane-spanning nanopore, and wherein the at least one hydrophobically-modified polynucleotide strand hybridises to a portion of the at least one scaffold polynucleotide strand, the membrane-spanning nanopore defining a central channel with a minimum internal width of at least about 5 nm. Membranes comprising the membrane-spanning nanopore and applications of those membranes are also provided. | 2019-10-10 |
20190309351 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS - Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations. | 2019-10-10 |
20190309352 | MULTIMODAL ASSAY FOR DETECTING NUCLEIC ACID ABERRATIONS - The invention provides methods for determining whether a subject is predisposed to the disease or condition, or for diagnosing a disease or condition, or for detecting the state of a disease or condition, by detecting nucleic acid fragment size patterns, copy number variations, mutational landscape, genomic instability, methylation status, and combinations thereof in a subject. The invention further provides methods for selecting nucleic acid molecules for use in the methods of the invention. | 2019-10-10 |
20190309353 | Spatially Encoded Biological Assays - The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature. | 2019-10-10 |
20190309354 | Spatially Encoded Biological Assays - The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature. | 2019-10-10 |
20190309355 | Spatially Encoded Biological Assays - The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature. | 2019-10-10 |
20190309356 | Colorimetric Detection of Nucleic Acid Amplification - Colorimetry is used to detect amplification reaction products. A sample is contacted with a reaction mix under conditions such that an amplification reaction occurs and produces an amplification reaction product if the sample contains a target nucleic acid template molecule. The reaction mix includes an enzyme for catalyzing the amplification reaction, and at least one halochromic agent. If the target nucleic acid template molecule is present, the amplification reaction changes the starting pH of the reaction mix to cause a detectable colorimetric change of the halochromic agent, thereby indicating the presence of the target nucleic acid. If the target nucleic acid template molecule is not present, the amplification reaction does not generate an adequate number of protons to sufficiently change the starting pH of the reaction mix to cause a detectable colorimetric change of the halochromic agent, thereby indicating that the amplification reaction product has not been produced. | 2019-10-10 |
20190309357 | CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS - The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA. | 2019-10-10 |
20190309358 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING - The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising DNA from both the mother of the fetus and from the fetus, and optionally from genotypic data from the mother and father. The ploidy state is determined by using a joint distribution model to create a plurality of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR. | 2019-10-10 |
20190309359 | COMPOSITIONS AND METHODS FOR IDENTIFYING NUCLEIC ACID MOLECULES - The present disclosure provides methods and compositions for sequencing nucleic acid molecules and identifying individual sample nucleic acid molecules using Molecular Index Tags (MITs). Furthermore, reaction mixtures, kits, and adapter libraries are provided. | 2019-10-10 |
20190309360 | PRESERVING GENOMIC CONNECTIVITY INFORMATION IN FRAGMENTED GENOMIC DNA SAMPLES - A method of sequencing a target nucleic acid polymer by (a) modifying a target nucleic acid polymer to produce a modified nucleic acid polymer; (b) producing fragments of the modified nucleic acid polymer, wherein the fragments are attached to locations on a solid support surface (c) determining nucleotide sequences from the fragments at the locations; and (d) producing a representation of the nucleotide sequence for the target nucleic acid polymer based on the nucleotide sequences from the fragments and the relative distances between the locations on the solid support surface. | 2019-10-10 |
20190309361 | INTEGRATED ANALYTICAL SYSTEM AND METHOD - An analytical assembly within a unified device structure for integration into an analytical system. The analytical assembly is scalable and includes a plurality of analytical devices, each of which includes a reaction cell, an optical sensor, and at least one optical element positioned in optical communication with both the reaction cell and the sensor and which delivers optical signals from the cell to the sensor. Additional elements are optionally integrated into the analytical assembly. Methods for forming and operating the analytical system are also disclosed. | 2019-10-10 |
20190309362 | Transposition of Native Chromatin for Personal Epigenomics - Provided herein is a method for analyzing polynucleotides such as genomic DNA. In certain embodiments, the method comprises: (a) treating chromatin isolated from a population of cells with an insertional enzyme complex to produce tagged fragments of genomic DNA; (b) sequencing a portion of the tagged fragments to produce a plurality of sequence reads; and (c) making an epigenetic map of a region of the genome of the cells by mapping information obtained from the sequence reads to the region. A kit for performing the method is also provided. | 2019-10-10 |
20190309363 | METHODS FOR PREPARING TAGGING OLIGONUCLEOTIDES - The present invention relates to technologies for preparing a tagging oligonucleotide. By analyzing exquisitely a non-complementarity level of a first tagging part, the first aspect of the present invention permits to more efficiently and easily select a suitable tagging sequence among a multitude of sequences generated theoretically. In addition, according to the second aspect of the present invention, when a nucleotide sequence for a tagging portion is first selected, one or more regions in a target nucleic acid sequence having a non-complementarity level to the nucleotide sequence for the tagging portion are found, and then a nucleotide sequence for a targeting portion is determined, tagging oligonucleotides for detecting various target nucleic acid sequences can prepared by using the fewest number of nucleotide sequences for the tagging portion and a third template. | 2019-10-10 |
20190309365 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI - The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons. | 2019-10-10 |
20190309366 | CXR4 as a Susceptibility Locus in Juvenile Idiopathic Arthritis (JIA) and Methods of Use Thereof for the Treatment and Diagnosis of the Same - Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed. | 2019-10-10 |